The field of gene and cell therapy is one of the fastest-growing areas in biotechnology today. At the heart of this transformation lies viral vector manufacturing, a process that enables scientists to deliver genetic material into cells for therapeutic purposes. As the world moves toward advanced, targeted treatments, viral vectors are emerging as one of the most critical tools in modern medicine.
According to BCC Research, the global viral vector manufacturing market is expected to grow from $6.3 billion in 2025 to $18.8 billion by 2030, registering a compound annual growth rate (CAGR) of 24.6% during the forecast period. This impressive expansion reflects both the medical breakthroughs and the increasing demand for safe, efficient, and scalable production technologies.
Viral vectors are modified viruses that have been engineered to deliver therapeutic genes into human cells. In this process, disease-causing components of the virus are removed, and beneficial genetic material is inserted in their place. The virus then acts as a delivery vehicle, transferring healthy or corrective genes into targeted cells.
These vectors are the foundation of gene and cell therapies, which aim to treat diseases at their genetic root rather than just manage symptoms. They are also used in vaccine development, oncology research, and immunotherapy, making them vital across multiple medical disciplines.
Common types of viral vectors include: